RGNX
Income statement / Annual
Last year (2025), Regenxbio Inc's total revenue was $170.44 M,
an increase of 104.54% from the previous year.
In 2025, Regenxbio Inc's net income was -$193.88 M.
See Regenxbio Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$170.44 M |
$83.33 M |
$90.24 M |
$112.72 M |
$470.35 M |
$154.57 M |
$35.23 M |
$218.51 M |
$10.39 M |
$4.59 M |
| Cost of Revenue |
$20.30 M
|
$33.57 M
|
$37.21 M
|
$54.55 M
|
$51.83 M
|
$35.71 M
|
$8.24 M
|
$9.64 M
|
$1.71 M
|
$959.00 K
|
| Gross Profit |
$150.14 M
|
$49.76 M
|
$53.03 M
|
$58.18 M
|
$418.51 M
|
$118.85 M
|
$26.99 M
|
$208.87 M
|
$8.68 M
|
$3.63 M
|
| Gross Profit Ratio |
0.88
|
0.6
|
0.59
|
0.52
|
0.89
|
0.77
|
0.77
|
0.96
|
0.84
|
0.79
|
| Research and Development Expenses |
$228.30 M
|
$208.52 M
|
$232.27 M
|
$242.45 M
|
$181.44 M
|
$166.29 M
|
$124.19 M
|
$83.87 M
|
$57.22 M
|
$45.48 M
|
| General & Administrative Expenses |
$82.86 M
|
$76.62 M
|
$88.49 M
|
$85.28 M
|
$79.33 M
|
$63.82 M
|
$51.82 M
|
$36.85 M
|
$27.23 M
|
$23.59 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$82.86 M
|
$76.62 M
|
$88.49 M
|
$85.28 M
|
$79.33 M
|
$63.82 M
|
$51.82 M
|
$36.85 M
|
$27.23 M
|
$23.59 M
|
| Other Expenses |
$179.00 K
|
-$2.03 M
|
$397.00 K
|
-$6.68 M
|
-$2.24 M
|
$7.98 M
|
-$10.00 K
|
$42.00 K
|
$116.00 K
|
-$102.00 K
|
| Operating Expenses |
$311.34 M
|
$283.11 M
|
$321.16 M
|
$321.06 M
|
$258.53 M
|
$238.09 M
|
$175.99 M
|
$120.77 M
|
$84.57 M
|
$68.97 M
|
| Cost And Expenses |
$331.64 M
|
$316.67 M
|
$358.37 M
|
$375.60 M
|
$310.37 M
|
$273.80 M
|
$184.23 M
|
$130.41 M
|
$86.28 M
|
$69.93 M
|
| Interest Income |
$12.27 M
|
$174.00 K
|
$25.00 K
|
$342.00 K
|
$719.00 K
|
$4.27 M
|
$2.95 M
|
$8.95 M
|
$0.00
|
$0.00
|
| Interest Expense |
$45.01 M
|
$12.66 M
|
$6.86 M
|
$23.25 M
|
$26.28 M
|
$771.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$15.62 M
|
$16.22 M
|
$17.32 M
|
$12.91 M
|
$9.56 M
|
$8.41 M
|
$7.15 M
|
$3.98 M
|
$2.69 M
|
$544.00 K
|
| EBITDA |
-$145.58 M |
-$198.23 M |
-$239.46 M |
-$244.24 M |
$169.54 M |
-$96.83 M |
-$90.34 M |
$92.08 M |
-$73.20 M |
-$64.80 M |
| EBITDA Ratio |
-0.85
|
-2.38
|
-2.65
|
-2.17
|
0.36
|
-0.63
|
-2.56
|
0.42
|
-7.04
|
-14.12
|
| Operating Income Ratio |
-0.95
|
-2.8
|
-2.97
|
-2.33
|
0.34
|
-0.77
|
-4.23
|
0.4
|
-7.3
|
-14.24
|
| Total Other Income/Expenses Net |
-$32.68 M
|
$6.24 M
|
$4.48 M
|
-$17.53 M
|
-$18.73 M
|
$13.22 M
|
$51.51 M
|
$16.02 M
|
$2.72 M
|
$1.94 M
|
| Income Before Tax |
-$193.88 M
|
-$227.10 M
|
-$263.65 M
|
-$280.41 M
|
$141.25 M
|
-$106.01 M
|
-$97.49 M
|
$104.12 M
|
-$73.17 M
|
-$63.40 M
|
| Income Before Tax Ratio |
-1.14
|
-2.73
|
-2.92
|
-2.49
|
0.3
|
-0.69
|
-2.77
|
0.48
|
-7.04
|
-13.82
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$152.00 K
|
-$84.00 K
|
$13.41 M
|
$5.24 M
|
-$2.76 M
|
$4.18 M
|
$686.00 K
|
-$435.00 K
|
| Net Income |
-$193.88 M
|
-$227.10 M
|
-$263.49 M
|
-$280.32 M
|
$127.84 M
|
-$111.25 M
|
-$94.73 M
|
$99.94 M
|
-$73.17 M
|
-$62.97 M
|
| Net Income Ratio |
-1.14
|
-2.73
|
-2.92
|
-2.49
|
0.27
|
-0.72
|
-2.69
|
0.46
|
-7.04
|
-13.72
|
| EPS |
-3.76 |
-4.59 |
-6.02 |
-6.5 |
3.01 |
-2.98 |
-2.58 |
2.73 |
-2.45 |
-2.38 |
| EPS Diluted |
-3.76 |
-4.59 |
-6.02 |
-6.5 |
2.91 |
-2.98 |
-2.58 |
2.73 |
-2.45 |
-2.38 |
| Weighted Average Shares Out |
$51.57 M
|
$49.51 M
|
$43.73 M
|
$43.15 M
|
$42.44 M
|
$37.28 M
|
$36.69 M
|
$36.61 M
|
$29.86 M
|
$26.41 M
|
| Weighted Average Shares Out Diluted |
$51.57 M
|
$49.51 M
|
$43.73 M
|
$43.15 M
|
$43.91 M
|
$37.28 M
|
$36.69 M
|
$36.65 M
|
$29.88 M
|
$26.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
